GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » Short-Term Debt

Biocure Technology (XCNQ:CURE) Short-Term Debt : C$0.00 Mil (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology Short-Term Debt?

Biocure Technology's Short-Term Debt for the quarter that ended in Sep. 2024 was C$0.00 Mil.

Biocure Technology's annual Short-Term Debt declined from Dec. 2021 (C$2.53 Mil) to Dec. 2022 (C$0.08 Mil) and declined from Dec. 2022 (C$0.08 Mil) to Dec. 2023 (C$0.00 Mil).


Biocure Technology Short-Term Debt Historical Data

The historical data trend for Biocure Technology's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology Short-Term Debt Chart

Biocure Technology Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 1.05 2.53 0.08 -

Biocure Technology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 - - - -

Biocure Technology Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Biocure Technology Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Biocure Technology's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocure Technology Business Description

Traded in Other Exchanges
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9
Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It Developing Biosimilars and CAR-T Cell pharmaceuticals. Its products are CAR-T Cell Therapy, Interferon Beta, Ranibizumab, and PEG-Filgrastim.
Executives
Konstantin Lichtenwald Director, Senior Officer

Biocure Technology Headlines